- Home
- DBI vs AVIR Comparison
DBI vs AVIR Comparison
Compare DBI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- AVIR
- Stock Information
- Founded
- DBI 1991
- AVIR 2012
- Country
- DBI United States
- AVIR United States
- Employees
- DBI N/A
- AVIR N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- DBI Consumer Discretionary
- AVIR Health Care
- Exchange
- DBI Nasdaq
- AVIR Nasdaq
- Market Cap
- DBI 287.2M
- AVIR 276.9M
- IPO Year
- DBI 1991
- AVIR 2020
- Fundamental
- Price
- DBI $4.88
- AVIR $3.25
- Analyst Decision
- DBI Hold
- AVIR Hold
- Analyst Count
- DBI 3
- AVIR 1
- Target Price
- DBI $6.50
- AVIR $6.88
- AVG Volume (30 Days)
- DBI 1.5M
- AVIR 178.7K
- Earning Date
- DBI 12-10-2024
- AVIR 11-07-2024
- Dividend Yield
- DBI 4.12%
- AVIR N/A
- EPS Growth
- DBI N/A
- AVIR N/A
- EPS
- DBI N/A
- AVIR N/A
- Revenue
- DBI $3,059,173,000.00
- AVIR N/A
- Revenue This Year
- DBI $0.78
- AVIR N/A
- Revenue Next Year
- DBI $3.19
- AVIR N/A
- P/E Ratio
- DBI N/A
- AVIR N/A
- Revenue Growth
- DBI N/A
- AVIR N/A
- 52 Week Low
- DBI $4.36
- AVIR $2.81
- 52 Week High
- DBI $12.84
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- DBI 38.18
- AVIR 44.03
- Support Level
- DBI $4.58
- AVIR $3.10
- Resistance Level
- DBI $4.96
- AVIR $3.48
- Average True Range (ATR)
- DBI 0.30
- AVIR 0.13
- MACD
- DBI 0.01
- AVIR -0.01
- Stochastic Oscillator
- DBI 33.71
- AVIR 29.52
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).